The aim of the current study is to determine whether
butein (3,4,2',4'-tetrahydroxychalcone) exhibits antiproliferative effects against
tumor cells through suppression of the
signal transducer and activator of transcription 3 (STAT3) activation pathway. We investigated the effects of
butein on constitutive and inducible STAT3 activation, role of
tyrosine kinases and
phosphatases in STAT3 activation, STAT3-regulated gene products, and growth modulation of
tumor cells. We found that this
chalcone inhibited both constitutive and interleukin-6-inducible STAT3 activation in
multiple myeloma (MM) cells. The suppression was mediated through the inhibition of activation of the upstream
kinases c-Src, Janus-like
kinase (JAK) 1, and JAK2.
Vanadate treatment reversed the
butein-induced down-regulation of STAT3 activation, suggesting the involvement of a
tyrosine phosphatase. Indeed, we found that
butein induced the expression of the
tyrosine phosphatase SHP-1 and deletion of SHP-1 gene by
small interfering RNA abolished the ability of
butein to inhibit STAT3 activation, suggesting the critical role of SHP-1 in the action of this
chalcone.
Butein down-regulated the expression of STAT3-regulated gene products such as Bcl-xL, Bcl-2,
cyclin D1, and Mcl-1, and this led to the suppression of proliferation and induction of apoptosis. Consistent with these results, overexpression of constitutive active STAT3 significantly reduced the
butein-induced apoptosis. Moreover, we found that
butein significantly potentiated the apoptotic effects of
thalidomide and
Velcade in MM cells. Overall, these results suggest that
butein is a novel blocker of STAT3 activation and thus may have potential in suppression of
tumor cell proliferation and reversal of chemoresistance in MM cells.